Oramed Pharmaceuticals (ORMP) Other Non-Current Liabilities (2011 - 2024)
Oramed Pharmaceuticals (ORMP) posted Other Non-Current Liabilities of $60000.0 for Q4 2024, little changed on a QoQ basis from $60000.0 in Q3 2024, and up 445.45% year-over-year from $11000.0 in Q1 2024.
Oramed Pharmaceuticals (ORMP) Other Non-Current Liabilities (2011 - 2024) Analysis & Trends
Oramed Pharmaceuticals' Other Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $60000.0 for Q4 2024.
- Quarterly Other Non-Current Liabilities rose 445.45% year-over-year to $60000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $60000.0 (up 445.45% YoY) and the FY2024 annual result came in at $60000.0, up 445.45% from the prior year.
- Other Non-Current Liabilities was $60000.0 for Q4 2024 at Oramed Pharmaceuticals, roughly flat from $60000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $6.9 million in Q3 2020 and bottomed at $11000.0 in Q2 2021.
- A 5-year average of $437000.0 and a median of $62000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2020 — Other Non-Current Liabilities soared 2463.47% — and 2021, when it plunged 98.22%.
- Oramed Pharmaceuticals' Other Non-Current Liabilities stood at $212000.0 in 2020, then slumped by 42.45% to $122000.0 in 2021, then plunged by 50.0% to $61000.0 in 2022, then slumped by 81.97% to $11000.0 in 2023, then surged by 445.45% to $60000.0 in 2024.
- Business Quant data shows ORMP's Other Non-Current Liabilities at $60000.0 in Q4 2024, $60000.0 in Q3 2024, and $60000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Oramed Pharmaceuticals | 170.25 Mn | 170.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Jun 30, 2024 | 60,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | 11,000.00 |
| Sep 30, 2023 | 61,000.00 |
| Jun 30, 2023 | 66,000.00 |
| Mar 31, 2023 | 59,000.00 |
| Dec 31, 2022 | 61,000.00 |
| Sep 30, 2022 | 61,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 99,000.00 |
| Nov 30, 2021 | 122,000.00 |
| Aug 31, 2021 | 124,000.00 |
| May 31, 2021 | 11,000.00 |
| Feb 28, 2021 | 177,000.00 |
| Nov 30, 2020 | 212,000.00 |
| Aug 31, 2020 | 6.95 Mn |
| May 31, 2020 | 194,000.00 |
| Feb 29, 2020 | 232,000.00 |